A Long-tem Efficacy, Safety, and Tolerability Study of BOTOX in Patients With Chronic Migraine

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jun 2020 Results presented at the 62nd Annual Scientific Meeting of the American Headache Society
20 Jun 2020 Results of post-hoc analysis assessing proportions of chronic migraine patients reductions in headache days treated with onabotulinumtoxin A, presented at the 62nd Annual Scientific Meeting of the American Headache Society.
15 Jun 2020 According to an AbbVie media release, data from this trial will be presented at the Virtual 2020 Annual Scientific Meeting of the American Headache Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com